Peri-transplant ruxolitinib for GVHD prevention

Current understanding

To be populated as evidence accumulates.

Evidence log

• 2026-07-20 — Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis: Phase II extension cohort (trial-early) in reduced-intensity haploidentical HCT for primary/secondary MF: after a prior pre-transplant-only JAKi cohort produced universal engraftment but high GVHD, a peri-transplant (before, during, and after HCT) JAK inhibitor schedule is being tested specifically to reduce GVHD without raising graft failure — provides direct within-protocol rationale for continuous peri-transplant JAKi exposure in the haplo-RIC setting. (novelty: 3)
• 2026-06-03 — Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant: cross-connection with hyperbaric-oxygen-therapy-allo-hsct: Both are peri-transplant interventions targeting GVHD prevention/mitigation in MPN and related myeloid malignancies undergoing allo-HSCT, though via distinct mechanisms (oxygen-based supportive care vs. JAK inhibition). (novelty: 4)
• Foundation — FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases: cross-connection with cd24fc-gvhd-prevention-mpn: Both are GVHD-prevention strategies in the MPN transplant setting, representing parallel pharmacologic approaches (immunomodulatory fusion protein vs JAK inhibition). (novelty: 3)
• 2026-02-19 — Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: Phase II trial (trial-early) evaluating ruxolitinib added to tacrolimus/methotrexate GVHD prophylaxis before, during, and after allogeneic HCT specifically in older patients with myelofibrosis or MDS/MPN overlap syndromes — extends the peri-transplant ruxolitinib paradigm to an older population, MDS/MPN overlap indication, and a tacrolimus/MTX (rather than tacrolimus/sirolimus) backbone. (novelty: 3)
• 2026-03-13 — Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis: cross-connection with gecacitinib-jak-acvr1-inhibitor: Both protocols deploy JAK inhibitors across the peri-transplant window for MF, though with differing primary endpoints (disease control vs. GVHD prevention). (novelty: 3)
• 2026-04-14 — Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis: Phase II trial (trial-early) evaluating ruxolitinib administered before, during, and after allogeneic HSCT in primary and secondary myelofibrosis, with GVHD incidence/severity, survival, and quality of life as endpoints — formalizes the peri-transplant protocol beyond bridging-only use. (novelty: 3)

Open questions

Related